Juergen Reichardt

Dr. Juergen Reichardt

Australian Institute of Tropical Health and Medicine (AITHM) James Cook University E1.003D, Smithfield QLD 4878 Australia

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in The Lancet
Verified
Journal Article
Closed access
NMNick M Makridakis
Nick M Makridakis
RRRonald K Ross
Ronald K Ross
MPMalcolm C Pike
Malcolm C Pike
LCLaura E Crocitto
Laura E Crocitto
LKLaurence N Kolonel
Laurence N Kolonel
Juergen ReichardtJuergen Reichardt
Juergen Reichardt

27 March 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RMR. Mehrian-Shai
R. Mehrian-Shai
CCC. D. Chen
C. D. Chen
TST. Shi
T. Shi
SHS. Horvath
S. Horvath
SNS. F. Nelson
S. F. Nelson
CSC. L. Sawyers
C. L. Sawyers
PTEN is an important tumor-suppressor gene associated with many cancers. Through expression profiling of glioblastoma tissue samples and prostate cancer xenografts, we identified a molecular signature for loss of the PTEN tumor suppressor in glioblastoma and prostate tumors. The PTEN signature consists of a minimum of nine genes, several of which are involved in various pathways already implicated in tumor formation. Among these signature genes, the most significant was an increase in insulin growth factor-binding protein 2 (IGFBP-2) mRNA. Up-regulation of IGFBP-2 was confirmed at the protein level by Western blot analysis and validated in samples not included in the microarray analysis. The link between IGFBP-2 and PTEN was of particular interest because elevated serum IGFBP-2 levels have been reported in patients with prostate and brain tumors. To further investigate this link, we determined that IGFBP-2 expression is negatively regulated by PTEN and positively regulated by phosphatidylinositol 3-kinase (PI3K) and Akt activation. In addition, Akt-driven transformation is impaired in IGFBP2 −/− mouse embryo fibroblasts, implicating a functional role for IGFBP-2 in PTEN signaling. Collectively, these studies establish that PTEN and IGFBP-2 expression are inversely correlated in human brain and prostate cancers and implicate serum IGFBP-2 levels as a potential serum biomarker of PTEN status and PI3K Akt pathway activation in cancer patients.

1 July 2000 in Pharmacogenetics
Verified
Journal Article
Closed access
NMNick M. Makridakis
Nick M. Makridakis
ESEnrico di Salle
Enrico di Salle
Juergen ReichardtJuergen Reichardt
Juergen Reichardt
Human prostatic steroid 5α-reductase, encoded by the SRD5A2 gene on chromosome band 2p23, catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate, with NADPH as its cofactor. This enzyme has never been purified but a number of competitive inhibitors have been developed for this enzyme since increased steroid 5α-reductase activity may cause benign prostatic hypertrophy and prostate cancer. We report here the detailed biochemical and pharmacogenetic dissection of the human enzyme by analysing 10 missense substitutions and three double mutants which are all naturally found in humans. Nine of these 13 mutants reduce activity (measured as Vmax) by 20% or more, three increase steroid 5α-reductase by more than 15% and one results in essentially unaltered kinetic properties suggesting that it is a truly neutral (`polymorphic') amino acid substitution. Substantial pharmacogenetic variation among the mutants was also observed when three competitive inhibitors, finasteride, GG745 (dutasteride) and PNU157706, were investigated. Our studies not only define the substrate and cofactor binding sites of human steroid 5α-reductase, but also have significant consequences for the pharmacological usage of steroid 5α-reductase inhibitors in human patients treated for prostatic conditions.

17 June 2002 in The Prostate
Verified
Journal Article
Closed access
PDF file
AHAnn W. Hsing
Ann W. Hsing
Juergen ReichardtJuergen Reichardt
Juergen Reichardt
FSFrank Z. Stanczyk
Frank Z. Stanczyk

16 June 1999 in Human Mutation
Verified
Journal Article
Closed access
PDF file
LTLinda Tyfield
Linda Tyfield
Juergen ReichardtJuergen Reichardt
Juergen Reichardt
JFJudy Fridovich-Keil
Judy Fridovich-Keil
DCDavid T. Croke
David T. Croke
LELouis J. Elsas
Louis J. Elsas
MBMa Dolores Boleda
Ma Dolores Boleda
Classical galactosemia is caused by a deficiency in activity of the enzyme galactose‐1‐phosphate uridyl transferase (GALT), which, in turn, is caused by mutations at the GALT gene. The disorder exhibits considerable allelic heterogeneity and, at the end of 1998, more than 150 different base changes were recorded in 24 different populations and ethnic groups in 15 countries worldwide. The mutations most frequently cited are Q188R, K285N, S135L, and N314D. Q188R is the most common mutation in European populations or in those predominantly of European descent. Overall, it accounts for 60–70% of mutant chromosomes, but there are significant differences in its relative frequency in individual populations. Individuals homoallelic for Q188R tend to have a severe phenotype and this is in keeping with the virtually complete loss of enzyme activity observed in in vitro expression systems. Globally, K285N is rarer, but in many European populations it can be found on 25–40% of mutant chromosomes. It is invariably associated with a severe phenotype. S135L is found almost exclusively in African Americans. In vitro expression results are discrepant, but some individuals carrying S135L appear to exhibit GALT activity in some tissues. Duarte 1 (or Los Angeles) and Duarte 2 (or Duarte) variants carry the same amino acid substitution, N314D, even though D1 is associated with increased erythrocyte GALT activity and D2 with reduced activity. N314D is in linkage disequilibrium with other base changes that differ on the D1 and D2 alleles. N314D does not impair GALT activity in in vitro expression systems. However, there are differences in the abundance of GALT protein in lymphoblastoid cells lines from D2 and D1 individuals. It is unclear whether the specific molecular changes that distinguish the D1 and D2 alleles account for the different activities. The considerable genetic heterogeneity documented to date undoubtedly contributes to the phenotypic heterogeneity that is observed in galactosemia. The additional effects of nonallelic variation and other constitutional factors on phenotypic variability remain to be elucidated. Hum Mutat 13:417–430, 1999.

1 June 2022 in Human Genomics
Verified
Journal Article
Open access
PDF file
Michela BiancolellaMichela Biancolella
Michela Biancolella
VCVito Luigi Colona
Vito Luigi Colona
RMRuty Mehrian-Shai
Ruty Mehrian-Shai
JWJessica Lee Watt
Jessica Lee Watt
LLLucio Luzzatto
Lucio Luzzatto
Juergen ReichardtJuergen Reichardt
Juergen Reichardt
COVID-19, which is caused by the SARS-CoV-2, has ravaged the world for the past 2 years. Here, we review the current state of research into the disease with focus on its history, human genetics and genomics and the transition from the pandemic to the endemic phase. We are particularly concerned by the lack of solid information from the initial phases of the pandemic that highlighted the necessity for better preparation to face similar future threats. On the other hand, we are gratified by the progress into human genetic susceptibility investigations and we believe now is the time to explore the transition from the pandemic to the endemic phase. The latter will require worldwide vigilance and cooperation, especially in emerging countries. In the transition to the endemic phase, vaccination rates have lagged and developed countries should assist, as warranted, in bolstering vaccination rates worldwide. We also discuss the current status of vaccines and the outlook for COVID-19.